Interestingly, in the cancer survivor group, MMP9, and Osteopontin, both known to promote disease progression63,64, had significant positive correlations with the marginalization scale of barriers in access to care (Fig. 4c and Supplemental Fig. 2c). Here, MMP9 is linked to cancer.